High prevalence of autoantibodies against phosphoglycerate mutase 1 in patients with autoimmune central nervous system diseases

J Neuroimmunol. 2010 Feb 26;219(1-2):105-8. doi: 10.1016/j.jneuroim.2009.11.014. Epub 2009 Dec 6.

Abstract

We identified the autoantibody against phosphoglycerate mutase 1 (PGAM1), which is a glycolytic enzyme, in sera from multiple sclerosis (MS) patients by proteomics-based analysis. We further searched this autoantibody in sera from patients with other neurological diseases. The prevalence of the anti-PGAM1 antibody is much higher in patients with MS and neuromyelitis optica (NMO) than in those with other neurological diseases and in healthy controls. It was reported that the anti-PGAM1 antibody is frequently detected in patients with autoimmune hepatitis (AIH). Results of our study suggest that the anti-PGAM1 antibody is not only a marker of AIH but also a nonspecific marker of central nervous system autoimmune diseases.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Animals
  • Autoantibodies / blood*
  • Demyelinating Autoimmune Diseases, CNS / blood*
  • Demyelinating Autoimmune Diseases, CNS / classification
  • Demyelinating Autoimmune Diseases, CNS / epidemiology
  • Demyelinating Autoimmune Diseases, CNS / immunology*
  • Electrophoresis, Gel, Two-Dimensional / methods
  • Female
  • Humans
  • Male
  • Mass Spectrometry / methods
  • Middle Aged
  • Nervous System Diseases / blood
  • Nervous System Diseases / immunology
  • Phosphoglycerate Mutase / immunology*
  • Rats
  • Young Adult

Substances

  • Autoantibodies
  • Phosphoglycerate Mutase